Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing's syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NASDAQ:SBBP
- CUSIP: N/A
- Web: www.strongbridgebio.com
- Market Cap: $166.07 million
- Outstanding Shares: 35,335,000
- 50 Day Moving Avg: $4.37
- 200 Day Moving Avg: $3.57
- 52 Week Range: $2.00 - $6.24
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.70
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $1.09 per share
- Price / Book: 4.31
- EBIDTA: ($34,900,000.00)
- Return on Equity: -50.52%
- Return on Assets: -47.00%
- Current Ratio: 6.08%
- Quick Ratio: 6.08%
- Average Volume: 52,642 shs.
- Beta: 2.75
- Short Ratio: 3.37
Frequently Asked Questions for Strongbridge Biopharma plc (NASDAQ:SBBP)
What is Strongbridge Biopharma plc's stock symbol?
Strongbridge Biopharma plc trades on the NASDAQ under the ticker symbol "SBBP."
How were Strongbridge Biopharma plc's earnings last quarter?
Strongbridge Biopharma plc (NASDAQ:SBBP) issued its earnings results on Tuesday, May, 16th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.49) by $0.16. View Strongbridge Biopharma plc's Earnings History.
Where is Strongbridge Biopharma plc's stock going? Where will Strongbridge Biopharma plc's stock price be in 2017?
2 brokerages have issued twelve-month target prices for Strongbridge Biopharma plc's shares. Their predictions range from $10.00 to $18.00. On average, they expect Strongbridge Biopharma plc's stock price to reach $14.00 in the next year. View Analyst Ratings for Strongbridge Biopharma plc.
Who are some of Strongbridge Biopharma plc's key competitors?
Some companies that are related to Strongbridge Biopharma plc include Corbus Pharmaceuticals Holdings (CRBP), GlycoMimetics (GLYC), Ocular Therapeutix (OCUL), Nantkwest (NK), Minerva Neurosciences (NERV), Edge Therapeutics (EDGE), Sinovac Biotech (SVA), Concert Pharmaceuticals (CNCE), Ignyta (RXDX), Novavax (NVAX), Dynavax Technologies (DVAX), XBiotech (XBIT), Veracyte (VCYT), Nabriva Therapeutics AG - (NBRV), SIGA Technologies (SIGA), Kamada Ltd (KMDA), Compugen (CGEN) and Curis (CRIS).
Who owns Strongbridge Biopharma plc stock?
Strongbridge Biopharma plc's stock is owned by a variety of of retail and institutional investors. Top institutional investors include NEA Management Company LLC (11.72%), Broadfin Capital LLC (8.44%), Boxer Capital LLC (2.66%), Tredje AP fonden (2.57%) and Granite Point Capital Management L.P. (1.68%). View Institutional Ownership Trends for Strongbridge Biopharma plc.
Who sold Strongbridge Biopharma plc stock? Who is selling Strongbridge Biopharma plc stock?
Who bought Strongbridge Biopharma plc stock? Who is buying Strongbridge Biopharma plc stock?
How do I buy Strongbridge Biopharma plc stock?
Shares of Strongbridge Biopharma plc can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Strongbridge Biopharma plc stock cost?
One share of Strongbridge Biopharma plc stock can currently be purchased for approximately $4.70.
Earnings History for Strongbridge Biopharma plc (NASDAQ:SBBP)Earnings History by Quarter for Strongbridge Biopharma plc (NASDAQ:SBBP)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Strongbridge Biopharma plc (NASDAQ:SBBP)
Current Year EPS Consensus Estimate: $-2.06 EPS
Next Year EPS Consensus Estimate: $-1.27 EPS
Dividend History for Strongbridge Biopharma plc (NASDAQ:SBBP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Strongbridge Biopharma plc (NASDAQ:SBBP)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Strongbridge Biopharma plc (NASDAQ:SBBP)
Latest Headlines for Strongbridge Biopharma plc (NASDAQ:SBBP)
Strongbridge Biopharma plc (SBBP) Chart for Sunday, May, 28, 2017